A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
Status:
Completed
Trial end date:
2019-06-15
Target enrollment:
Participant gender:
Summary
This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of
brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable,
and adequate antidepressant therapy (ADT) in the treatment of adults with Major Depressive
Disorder with Treatment Resistant Depression.